Eli Lilly's Foundayo (orforglipron) showed in post-hoc analyses of the ATTAIN-1 trial a significant reduction in predicted 10-year risks of type 2 diabetes and cardiovascular disease among adults with obesity or overweight with related health issues. At 72 weeks, the highest dose of Foundayo (17.2 mg) reduced type 2 diabetes risk by 57% and cardiovascular disease risk by 18% compared to placebo. These findings suggest Foundayo not only aids weight loss but may also lower long-term health risks and healthcare costs. The drug is FDA-approved for chronic weight management and is being studied for other conditions like type 2 diabetes and sleep apnea.
Eli Lilly And Co (LLY) shares are trading at USD 1,158.00 with a slight 0.08% increase as of Oct 01, 2026 18:12 WIB on Pluang. The stock's market cap stands at $1.03 trillion, reflecting its significant presence in the health sector. Most Pluang investors currently favor buying LLY, with 77% of order activity leaning that way.
The Phase 3 ACHIEVE-4 trial found that Foundayo (orforglipron) reduced the risk of major cardiovascular events by 16% and cardiovascular death by 53% compared to insulin glargine in adults with type 2 diabetes and obesity. It also improved blood suga...
EBGLYSS (lebrikizumab-lbkz) monotherapy achieved its primary endpoint in the Phase 3b ADtouch trial, with over half of patients showing clear or almost clear skin on hands and feet by Week 16. The treatment also provided significant itch and pain rel...
Novo Nordisk's analysis of real-world data shows that patients who switched from obesity injections like Wegovy or Lilly's Zepbound to Novo's new Wegovy pill continued to lose weight, shedding about 4% of their body weight on average after three mont...
Eli Lilly is growing faster than any other large drugmaker, driven by strong sales of Mounjaro and new FDA approvals for cardiovascular risk reduction and insulin products. The company plans to seek approval for retatrutide in early 2027, a drug show...
Navitas Semiconductor's shares rose 12% premarket after securing a U.S. Army contract to develop next-generation silicon carbide power semiconductor technology. This project aims to create a domestic manufacturing process for ultra-high-voltage silic...
